814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity

• Mark Throsby,
• Arpita Mondal,
• Kees Bol,
• Wilfred Marissen,
• Jeroen Elaissais-Schaap,
• Paul Tacken,
• Steef Engels,
• Liang-Chuan Wang,
• Alan Roberts,
• Patrick Mayes,
• Cecile Geuijen

Affiliations

Mark Throsby

Aff394 Merus N.V. Utrecht Netherlands

Arpita Mondal

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

Kees Bol

1Merus N.V., Utrecht, Netherlands

Wilfred Marissen

1Merus N.V., Utrecht, Netherlands

Jeroen Elaissais-Schaap

2PD-Value BV, Utrecht, Netherlands

Paul Tacken

1Merus N.V., Utrecht, Netherlands

Steef Engels

1Merus N.V., Utrecht, Netherlands

Liang-Chuan Wang

3Incyte Corporation, Wilmington, DE, USA

Alan Roberts

3Incyte Corporation, Wilmington, DE, USA

Patrick Mayes

3Incyte Corporation, Wilmington, DE, USA

Cecile Geuijen

1Merus N.V., Utrecht, Netherlands